Results 51 to 60 of about 55,621 (311)

Limbic Encephalitis following Allogeneic Hematopoietic Stem Cell Transplantation

open access: yesCase Reports in Immunology, 2022
A woman with myelodysplastic syndrome (MDS) was treated with allogeneic hematopoietic stem cell transplantation (allo-HSCT). 65 days after the transplantation, she developed fatigue and central neurological symptoms.
Silje Johansen   +4 more
doaj   +1 more source

Intravenous immunoglobulins control scleromyxoedema [PDF]

open access: yesAnnals of the Rheumatic Diseases, 2002
Scleromyxoedema is a variant of papular mucinosis affecting the skin and internal organs. The different therapeutic approaches proposed for scleromyxoedema are still unsatisfactory. Intravenous immunoglobulin (IVIg) has been successfully employed in the treatment of connective tissue diseases and vasculitides.The successful treatment of three cases of ...
RIGHI, ANNA   +7 more
openaire   +4 more sources

In‐Depth Profiling Highlights the Effect of Efgartigimod on Peripheral Innate and Adaptive Immune Cells in Myasthenia Gravis

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Myasthenia gravis (MG) is an autoimmune disorder characterized by antibody‐mediated complement activation. Efgartigimod, a neonatal Fc receptor (FcRn) antagonist, is approved for treating generalized MG (gMG). However, its modulatory effects on upstream innate and adaptive immune cells remain largely unexplored.
Lei Jin   +11 more
wiley   +1 more source

Bortezomib-containing multimodality treatment for antibody-mediated rejection with anti-HLA and anti-AT1R antibodies after kidney transplantation [PDF]

open access: yes, 2017
For decades, the human leukocyte antigen (HLA) complex has been considered the primary target of antibody-mediated rejection (AMR), and treatment strategies have mainly focused on anti-HLA antibodies.
Favi, Evaldo   +3 more
core   +1 more source

Remote Monitoring in Myasthenia Gravis: Exploring Symptom Variability

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Myasthenia gravis (MG) is a rare, autoimmune disorder characterized by fluctuating muscle weakness and potential life‐threatening crises. While continuous specialized care is essential, access barriers often delay timely interventions. To address this, we developed MyaLink, a telemedical platform for MG patients.
Maike Stein   +13 more
wiley   +1 more source

Acute kidney injury due to sucrose-containing intravenous immunoglobulins

open access: yesSaudi Journal of Kidney Diseases and Transplantation, 2019
Intravenous immunoglobulins (IVIGs) are pooled polyvalent immunoglobulin G antibodies extracted from the human plasma. Stabilizers in IVIG may include sugars, such as sucrose, glucose, or maltose.
Wasim Siddiqui   +5 more
doaj   +1 more source

An antivenin resistant, IVIg-corticosteroids responsive viper induced thrombocytopenia

open access: yesToxicology Reports, 2022
In this case report the hospital management of an acute, severe thrombocytopenia in a 57-year-old man in the north-east of Italy is reported. Thrombocytopenia developed immediately after the viper bite, despite the absence of clinical signs of ...
Matteo Turetta   +4 more
doaj   +1 more source

A resistant case of Kawasaki Disease [PDF]

open access: yes, 2007
Kawasaki disease (KD) is an acute febrile illness of childhood of unknown origin which may cause coronary arteritis and death. The Maltese incidence has been calculated at 3.2/100,000 population 4 years of age, similar to that reported in European ...
Grech, Victor E.   +2 more
core  

Explaining temporal trends in annualized relapse rates in placebo groups of randomized controlled trials in relapsing multiple sclerosis: systematic review and meta-regression

open access: yes, 2013
Background: Recent studies have shown a decrease in annualised relapse rates (ARRs) in placebo groups of randomised controlled trials (RCTs) in relapsing multiple sclerosis (RMS).
Friede, Tim   +5 more
core   +1 more source

Beneficial use of immunoglobulins in the treatment of Sydenham chorea [PDF]

open access: yes, 2010
This double case report indicates that treatment with intravenous immunoglobulins (IVIG) is effective in patients with Sydenham chorea (SC). SC is a rare but impressive clinical manifestation following streptococcal infection.
Tabitha D. van Immerzeel   +2 more
core   +2 more sources

Home - About - Disclaimer - Privacy